They were designed to help people eat less. And for millions of people, they have done exactly that. Medications like Ozempic, Wegovy, and Mounjaro have become some of the most prescribed drugs in the country, and the results people are seeing on the scale are hard to argue with. But there is a conversation that is not happening loudly enough. And as someone who works with people every day on rebuilding their bodies and their relationship with movement, I think it is worth having.

Some of the people taking these medications are reporting something unexpected. Not just losing the desire to eat. Losing the desire for things they used to love.

Here is a little context first. GLP-1 receptor agonists were originally developed to regulate blood sugar and appetite. They work by mimicking a hormone your gut naturally produces after eating, one that signals your brain that you are full.

The problem is that your brain has GLP-1 receptors scattered throughout it. Including in areas that have nothing to do with digestion.

One of those areas is the ventral tegmental area, or VTA. That is the brain’s primary dopamine reward hub. The region responsible for motivation, desire, pleasure, and the feeling that something is worth pursuing.

Researchers have found that when GLP-1 receptors in this region get activated, the dopamine response to rewarding stimuli gets blunted. In animal studies, rats given semaglutide showed significantly reduced alcohol consumption and reduced cocaine self-administration, not because they were sedated, but because the pull toward the reward simply faded.^[1]

That is the same mechanism making headlines right now. And in a lot of ways, it sounds like a good thing. Less craving for junk food, less pull toward alcohol, less obsessive thinking about substances. And the research does show real promise there.

But here is where it gets complicated.

Multiple clinicians and researchers are starting to flag something that is not showing up in the brochure.

A psychiatrist writing in a medical publication compared the pattern to the early days of SSRIs. When fluoxetine (Prozac) first came out, it was celebrated for reducing anxiety and improving personality. It took years before the full picture emerged, including emotional blunting, reduced libido, loss of motivation, and a subtle flattening of the inner emotional landscape.

The same psychiatrist is now observing a similar pattern with GLP-1 patients. People lose weight, sometimes dramatically, but report feeling “less alive.” Diminished desire. Reduced spontaneity. A quieting of the internal drive that makes daily life feel meaningful.^[3]

What begins as decreased appetite sometimes generalizes into decreased enthusiasm for socializing, intimacy, and creative pursuits.

To be clear, the research here is still developing and results are genuinely mixed. This is not settled science. But the signals are real enough that they deserve attention.

A 2024 systematic review found that GLP-1 receptor agonists consistently influenced reward-related behavior and may modulate dopamine signaling in ways that go far beyond appetite regulation. Researchers highlighted both the potential benefits for addiction and the need to understand the broader implications for motivation and reward processing.^[4]

To be fair, other large-scale analyses have not found the same results. A meta-analysis of 80 randomized clinical trials involving over 100,000 participants found no significant increase in psychiatric adverse events compared to placebo.^[7] And a study funded by the maker of semaglutide found that people without pre-existing mental health conditions were not more likely to develop depression or suicidal thoughts than controls.

So the picture is complicated. But the fact that findings are this inconsistent is itself a signal that something real is happening for a subset of people, and that we do not yet fully understand who is most at risk or why.

The FDA’s Adverse Event Reporting System has logged thousands of mood-related reports since 2022, including a subset specifically describing anhedonia, which is the clinical term for a reduced capacity to experience pleasure. The FDA has not issued a formal warning, and the significance of these reports is still being evaluated.^[1]

This one gets talked about even less.

A clinical review published in a peer-reviewed journal proposed that GLP-1 agonists may reduce sexual desire through increased serotonergic activity, a pathway separate from the dopamine system but still connected to drive and reward. The same review noted that this effect is likely being overlooked in clinical practice and called for longitudinal studies to properly measure it.^[8]

A pharmacovigilance study using FDA adverse event data from 2003 to 2024 identified a meaningful signal of male sexual dysfunction associated with GLP-1 receptor agonists, including decreased libido, erectile dysfunction, and orgasmic dysfunction. One analysis found that semaglutide use was associated with a notably higher incidence of newly diagnosed erectile dysfunction compared to non-users, particularly in non-diabetic men with obesity.^[9]

Again, these are signals and associations, not confirmed cause-and-effect relationships. But they are worth knowing about.

I am not here to tell anyone whether to take or not take these medications. That is between you and your doctor.

What I do believe is that people deserve to make informed decisions. And a decision is only truly informed when you have access to all the pieces, not just the ones that make it into mainstream coverage.

The body is a system. When you alter one pathway, it does not stay contained to that pathway. The same reward circuitry that drives unhealthy cravings also drives the joy you feel when you play with your kids, the motivation that gets you to the gym at 6 in the morning, the desire that keeps relationships alive, and the drive that pushes you toward meaningful work.

If you or someone you know is on one of these medications and noticing changes in mood, motivation, drive, or overall emotional engagement, that observation is valid. It is worth tracking, worth discussing with your prescribing physician, and worth not dismissing as “just stress.”

GLP-1 medications are genuinely changing lives. The weight loss results are real. The reduction in cravings for substances like alcohol has real clinical promise. There are people for whom these medications are a lifeline.

But the research is also telling us that the brain effects of these drugs are broader than we initially understood. And for a portion of the people taking them, the tradeoff may include a quieting of the very things that make life feel full.

More research is coming. Until then, awareness is the best tool we have.